
The CPT Editorial Panel has updated the Current Procedural Terminology (CPT) code set to include vaccine and administration codes that are unique to the COVID-19 vaccine candidate under development by Novavax Inc.
But we need to wait for the Novavax COVID-19 vaccine to receive approval or emergency use authorization from the U.S. Food and Drug Administration (FDA) before the provisional CPT codes will be effective for use. Indeed, Novavax said it plans to file for authorization with the FDA in the third quarter.
The Novavax COVID-19 vaccine joins other COVID-19 vaccines from AstraZeneca, Janssen (Johnson & Johnson), Moderna, and Pfizer, which will avoid possible supply disruptions.
So far, the CPT Editorial Panel has approved a total of 14 Category I codes for COVID-19 immunizations. These CPT codes are unique for each of the coronavirus vaccines, as well as administration codes unique to each such vaccine and dose.
